All In Biotech

NDA 016092 · Bausch

Edecrin

Ethacrynic Acid · Oral · Loop Diuretic

Novel

Last checked: Nov 20, 2026Latest source record: Mar 30, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1967

Jan 10, 1967

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

1 Phase 3, 1 recruiting

FAERS reports

553

400 serious, 66 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2023.

INDICATIONS AND USAGE Ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 10, 1967 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • EDECRIN · ETHACRYNIC ACID 25MG · TABLET, ORAL · Prescription · TE AB
  • EDECRIN · ETHACRYNIC ACID 50MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethacrynic Acid" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug reaction with eosinophilia and systemic symptoms59
  • off label use52
  • nausea48
  • dyspnoea43
  • drug ineffective35
  • acute kidney injury33
  • diarrhoea33
  • drug hypersensitivity33
  • fatigue32
  • vomiting32
  • asthenia26
  • death26

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20054
20069
20077
20089
20097
201012
201118
201231
201318
201415
201523
201627
201739
201830
201940
202028
202153
202243
202346
202425
202527
202633

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Edecrin (Ethacrynic Acid)

2024 spending

$587K

Beneficiaries

53

250 claims

Per beneficiary

$11,082

$23.76 per unit

View as table
YearSpending
2020$920,791
2021$765,609
2022$675,566
2023$517,004
2024$587,364

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 45 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.